#Baxdrostat Phase 3 – Uncontrolled/Resistant HTN : Strong BP reduction with low risk of high potassium #BaxHTN 📍794 pts on 2–3+ antihypertensives (incl. diuretic) 📍12-week treatment: Baxdrostat 1 mg, 2 mg, or placebo 📍Systolic BP ↓: 1 mg –14.5 mmHg, 2 mg –15.7 mmHg,

Olezarsen (Essence-TIMI 73b) antisense oligonucleotide binds to apoC-III mRNA. Inhibits production of apoC-III ➡️ ⬆️ breakdown & elimination of TGs. Subcutaneous monthly injection. Reduces TGs by ~60% No safety concerns #ESCCongress #Pharmacotherapy

A big step to broaden $IONS olezarsen’s use case beyond FCS presented at #ESCCongress by Brian Bergmark (this time without my misinterpretation of CV event rates! Thanks to Dirk Haussecker for catching).

Delighted to present our CarDS Lab work at #ESCCongress2025: 🤖 AI-enabled detection & prediction of AF from images of 12-lead ECG in sinus rhythm 🫀 Promising results in forecasting thromboembolic events and advancing 🎯prevention Rohan Khera Evangelos K. Oikonomou Lovedeep Dhingra

Aldosterone Synthase Inhibitors for Resistant Hypertension: Pharmacological Insights-A Systematic Review. Pharmacological comparison of ASls (baxdrostat, dexfadrostat, lorundrostat, LY3045697, osilodrostat). Via Federica Fogacci #ESCCongress doi.org/10.1007/s40265…

Pooled analyses of BROADWAY and BROOKLYN. Bodes well for $NAMS PREVAIL trial (obicetrapib CVOT). #ESCCongress

👉GAELp(a) Registry – ESC Congress 2025, Madrid 🇦🇷 First results from the Argentine National Registry on Lp(a) and Cardiovascular Risk (GAELp(a)): 🔹 Elevated Lp(a) in 31.4% of the cohort 🔹 Associated with higher risk of CAD, PAD and MACE 🔹 Independent predictor of

👉 Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study 🔬 Merck has announced positive results from the CORALreef Lipids Phase 3 trial, evaluating enlicitide decanoate, the

Building on the legacy of many, I'm incredibly excited that we have successfully translated our polygenic risk scores into a validated clinical assay Mass General Brigham Broad Institute, orderable by any clinician in the US today. 🧬To order: massgeneralbrigham.org/en/research-an… 🧬Announcement:

“Why am I forced to ask permission to do the right thing, repeatedly, and then defend it after the fact?” My clinic’s troubles pale in comparison, but reminds me that for many patients, every few months I have to hunt down the original labs and documents that show ASCVD or

A great figure from the European Society of Cardiology 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

A moving piece by Allison Jamison in AJPC that reflects the deep, multigenerational toll of FH, and the needless delays in diagnosis and treatment. FH is one of the lowest-hanging, highest-impact opportunities for EMR-based detection solutions.

Incredible trifecta by #JohnOstrominski in JACC Journals w #ESCCongress John is a one-of-a-kind talent, blending his joint CV & obesity fellowships, to lead a career in #CKM investigation. One to watch! 🚀 jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.…

In this NEJM letter, I highlight a growing issue in lipid trials: randomizing very high-risk patients to placebo and directing them to avoid adding proven therapies feels unethical. Yet trial populations often have far better risk factor control (and thus lower event rates) than

Confirmatory testing (aldosterone suppression testing) for primary aldosteronism: not reliable, or reproducible, for diagnosis or predicting lateralization. Sensitivity at the expense of specificity, and vice-versa. Time to simplify the process academic.oup.com/ejendo/article…

Novartis has entered the IL-6 space! Exciting times ahead as data on targeting residual inflammatory risk begin to emerge in the coming years.

High LDL from Familial Hypercholesterolemia (FH) & Homozygous FH (HoFH) impacts heart health at all ages. Join our webinar Sept. 16 at 3 PM ET with Dr. Duell, Sydney & her father, and Allison Jamison. 🔗 FamilyHeart.org/fh-and-hofh-we… #KnowFH #KnowHoFH #FHAwarenessDay

Lp(a) elevated in the setting of adverse pregnancy outcomes - is it the chicken or the egg? Erin D. Michos, M.D. and I review in our new editorial. UC San Diego Cardiology UC San Diego Cardiology Fellows Johns Hopkins Ciccarone Center sciencedirect.com/science/articl…

YES for cascade testing -- Lp(a) has a co-dominant inheritance meaning a gene from a single parent is enough to generate increased concentrations of Lp(a)-P. Thus, all first-degree relatives should be evaluated with this once in a lifetime test - can be life-saving to know